Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT01885455
Official study title

Improving Resection Rates Among African Americans With NSCLC

Study summary

This is a randomized, interventional trial in which the navigation is the intervention. Phase is not applicable. The study is a randomized trial to evaluate the impact of a nurse-led patient navigation intervention in improving rates of receipt of lung-directed therapy with curative intent (LDTCI) among African Americans with early stage lung cancer. Study sites are cluster-randomized to either the usual care study arm or the to the navigation intervention study arm. Randomization occurred at the level of the study site rather than at the level of individual participants. There are two arms.

Ask AI to explain this study
Start here

Key things to know

Main goalHealth Services Research

This describes the study’s primary purpose.

What is being studiedUsual Care and Intervention Arm

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Early-stage or resectable

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 12, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?10 U.S. locations

Locations may change over time.

Who runs it?Wake Forest University Health Sciences

Study sponsor

01
Study overview

What this study is about

Purpose
Health Services Research
Study type
Interventional
Phase
Not applicable
Sponsor
Wake Forest University Health Sciences
Interventions being studied
Other: Usual Care; Other: Intervention Arm
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Early-stage or resectable→
Treatment approach
Surgery→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • AA race
  • Clinically suspicious or biopsy-proven, early stage NSCLC, and
  • Ages 21 years and older
Reasons someone may not be able to joinExclusion criteria
  • Previous history of lung cancer
  • Spread of newly diagnosed probably/proven lung cancer to other part of the body
  • Diagnosis of synchronous cancer other than non-melanoma skin cancer or lung cancer, and
  • Receipt of surgical resection or radiosurgery for lung cancer since diagnosis with probable/proven lung cancer

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Beebe Healthcare Tunnell Cancer CenterLewes, Delaware
  • Saint Joseph's/Candler HospitalSavannah, Georgia
  • Stroger Hospital of Cook CountyChicago, Illinois
  • Ochsner NCORPNew Orleans, Louisiana
  • Beaumont Hospital - Royal OakRoyal Oak, Michigan
  • Metro-Minnesota NCORPSaint Louis Park, Minnesota
  • Nevada Cancer Research FoundationLas Vegas, Nevada
  • Wake Forest University Health SciencesWinston-Salem, North Carolina
  • Fox ChasePhiladelphia, Pennsylvania
  • Virginia Commonwealth UniversityRichmond, Virginia

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 12, 2020. Always confirm current availability with the study team.

View original record ↗